Operator
Ladies and gentlemen, good day and welcome to the Aequitas Chemicals Limited Q4 FY26 earnings conference call hosted by 360 ONE Capital. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.
Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. I now hand the conference over to Mr.
Rohit Nagraj from 360 ONE Capital. Thank you, and over to you, sir.
Please proceed.
Rohit Nagraj
Thanks, Shailendra. Good evening, everyone, and thank you for joining us on Aequitas Chemicals Q4 FY26 earnings conference call.
We thank the management for providing us the opportunity to host this call. Today, we have with us Aequitas Chemicals management, represented by Mr.
Nareshbhai Patel, Chairman and Managing Director; Mr. Abhishek Patel, Vice President Strategy; and Mr.
Bhavin Shah, Chief Financial Officer. I would like to invite Mr.
Bhavin Shah to initiate the proceedings now. Over to you, sir.
Thank you.
Bhavin Shah
Thank you, Rohit. Good evening, everyone.
We are pleased to welcome you all to our earnings conference call to discuss Q4 FY26 financials. Please note that a copy of our disclosure is available on the investor section of our website as well as on the stock exchanges.
Please do note that anything said on this call which reflects our outlook towards the future or which could be construed as forward-looking statement must be reviewed in conjunction with the risks that the company faces. The conference call is being recorded, and the transcript along with the audio of the same will be made available on the website of the company and exchanges.
Please also note that the audio on the conference call is the copyright material of Aequitas Chemicals and cannot be copied, rebroadcasted, or attributed in press or media without specific and written consent of the company. Now, I would like to hand over the floor to our Chairman and Managing Director, Mr.
Naresh Patel, for his opening statements. Over to you, sir.
Nareshkumar Ramjibhai Patel
Thank you, Bhavin. Good evening, everyone.
I hope you are all doing well. I will provide an overview of industry and about our future strategies before handing over to Abhishek for detailed business updates.
The chemical industry is once again navigated turbulent conditions driven by the ongoing conflict in the Gulf region, which has disrupted supply chain for key feedstocks and consequently pushed raw material prices higher. Shipping schedules and vessel availability have also been affected.
We are closely monitoring how the situation evolves. On our part, our procurement and operations teams have acted swiftly, and we do not anticipate any raw material shortage that would impact our production continuity.
On the demand side, momentum remains strong. New product inquiries continue to come in at a healthy pace, while demand for existing products remain robust.
We are working closely with our customers to ensure on-time delivery and unhindered supply through this period of market uncertainty. Turning to our strategic initiatives, I pleased to share that we are making strong progress on our journey to build a diversified multi-vertical chemicals company.
In our battery chemical business, the foundation is firmly in place. We have successfully commercialized our two first two—first two products and have a healthy pipeline of new products in development.
We expect to bring two additional products to commercial scale in FY27, further strengthening our revenue visibility backed by long-term customer contracts. In our semiconductor business, the product expansion strategy at BFC is clearly gaining traction.
New products other than HARIAS products are expected to be a meaningful contributor to growth in the coming year, and we will continue building on this momentum to establish BFC as sizeable business over the medium term. On Indichem, our South Korea joint venture, Abhishek will walk you through the capex details.
I am pleased to share that the R&D center is up and running. We have already started sending samples to prospective customers, a critical step that we expect will significantly reduce our time-to-market.
On the CDMO front, we continue to build a strong and differentiated pipeline. While commercialization in this business takes time, the ramp-up once initiated tends to be steep and swift.
Overall, I believe that by FY28—by FY28, our both businesses verticals, which are in investment phase now, battery chemicals and semiconductors, will have evolved into independent self-sustaining growth engines, each contributing meaningful to our top line along with pharmaceutical intermediate business. This multi-vertical model is central to our vision of building a truly diversified chemicals company.
Turning to our financial performance for the year, I am pleased to report that we have continued our strong growth trajectory, closing the year with revenue of ₹1,339 crore and our highest ever PAT of ₹356 crore. These results reflect the strength of our business model and the disciplined execution of our teams.
I will request Bhavin to take you through the detailed financial shortly. To conclude, we enter FY27 from a position of strength, with a clear strategy, a strong pipeline across all three verticals, and a proven track record of execution.
I am confident of delivering 25% revenue growth in FY27. With that, I would now like to hand over to our Vice President of Strategy, Abhishek Patel, who will walk you through the detailed business update.
Over to you, Abhishek.
Abhishek Patel
Thank you, Nareshbhai. Good evening, everyone.
Let me take this opportunity to share further insights into our business performance for the quarter. Starting with advanced pharmaceutical intermediate segment, this segment continued robust performance with revenue of ₹392.4 crore in Q4 FY26, reflecting a strong year-on-year growth of 43.9%.
Growth was primarily driven by CDMO business, complemented by steady contribution from our core advanced pharmaceutical intermediate segment. Here, I would like to mention that our process of reshuffling portfolio was mostly over during first nine months, and we have seen healthy growth in this business sequentially.
Moving on to the specialty chemical segment, revenue for this segment stood at ₹40.3 crore during the quarter, registering a steady year-on-year growth of 12.3%. Our commodity chemical subsegment recorded degrowth during the quarter, which was offset by strong recovery in BFC business.
Now turning to capital expenditure, capex for FY26 stood at ₹195 crore, primarily directed towards the Jhagadia site for battery chemical project, and then pilot plant at Sachin site, and maintenance capex. Let me provide some additional updates on our key projects.
Regarding the electrolyte additive capex at Jhagadia, the first phase of electrolyte capex is completed. The second phase of capex is currently ongoing and expected to get completed by Q1 FY27.
Pilot plant capex is slightly delayed due to delay in equipment arrival. It is now expected to get completed by Q2 FY27.
Apart from this, another major cash outlay during the year was our investment in South Korea joint venture, Indichem Inc. We have invested ₹190 crore in this JV during the year FY26.
Turning to our strategic infrastructure update, while Nareshbhai has covered our key growth drivers in detail, I would like to focus on the infrastructure that will support and enable growth in the years ahead. Our existing infrastructure is well positioned to support our growth through FY28.
However, looking further ahead, we have already began laying a groundwork for the next phase of infrastructure development, which will underpin our growth over the next 5 to 10 years. As immediate priority, we are embarking on ambitious expansion of our R&D center, one that will elevate it into world-class, internationally renowned facility, purpose-built to meet the demand of tomorrow's industry.
With planned 10x capacity expansion, the new center will feature dedicated sections spanning pharmaceuticals, battery chemicals, semiconductor, electronics, and cosmetics, etc. Each housed as a distinct divisions under one roof, bringing together deep specialization and power of cross-disciplinary innovations.
This is a defining investment for our future, designed to sustain our innovation pipeline and fuel long-term growth in the years ahead. In parallel, we are actively evaluating land acquisition opportunities to develop new infrastructure that will support our long-term growth ambitions.
Alongside physical infrastructure, a key pillar of strategy is deliberate migration of our portfolio towards higher-value products. The first step, a strategic reshuffling of our core advanced pharmaceutical portfolio, has been completed.
The next phase involves the systematic replacement of commodity chemical products with higher-value differentiated offerings. We will begin phasing out select commodity products this year, replacing them with a new product using same infrastructure with slight modification in calibrated phased manner.
Moving on, as Nareshbhai outlined, we are guiding 25% revenue growth in FY27. On margins, while we remain mindful of the near-term cost pressures stemming from global supply chain disruptions, we are confident in our ability to maintain EBITDA margin as a similar level in the coming year, underpinned by our product portfolio upgrade strategy and improving business mix.
I also want to highlight a key trend driven by our business cycle. Q1 is typically our weakest quarter, with revenue steadily increasing sequentially till Q4, which is always a strongest quarter.
This pattern results in H1 contributing around 40% of our top line, while H2 accounts for generally around 60%. With that, I will now hand over the floor to our Chief Financial Officer, Bhavin Shah, who will walk you through the detailed financial update.
Over to you, Bhavin.
Bhavin Shah
Thank you, Abhishek. I would like to briefly highlight the key performance metrics for the quarter and FY26 before we open the floor for questions.
Let me start with quarterly performance. Revenue from operations for the quarter reached ₹432.8 crore, representing 40.3% growth YoY.
Gross profit for the quarter was ₹268.3 crore, reflecting 83.8% increase compared to the same period last year. The gross margin expanded by 1,416 basis points YoY to 62%.
Gross margin was driven by improved product mix. EBITDA for the quarter was ₹183.5 crore, which represent more than twofold increase compared to the EBITDA of same period last year.
EBITDA margins were at 42.4%, up 1,487 basis points YoY. EBITDA margin was driven by expansion in gross margin as well as operating leverage.
PAT for the quarter was ₹134.3 crore, up 114.1% YoY. PAT margin for the quarter were 31%, which show an expansion of 1,070 basis points YoY.
Moving on the FY26 performance, revenue from operations for FY26 reached ₹1,339.4 crore, representing 33% increase YoY. EBITDA for the FY26 was ₹480.4 crore, which is 2x compared to the same period last year.
PAT for FY26 is at ₹356.4 crore, which more than doubled compared to the same period last year. Moving on to the balance sheet item, net cash and cash equivalent were at ₹198.3 crore as on 31st March 2026.
Our working capital for the year increased to 120 120 days from 114 days. There was some improvement in debtor and inventory days, which was offsetted by lower payable days.
With that, I request moderator to open the floor for questions. Thank you.
Operator
Thank you very much. We will now begin the question and answer session.
Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two.
Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.
We have first question from Rikin Shah from Boring AMC. Please go ahead.
Rikin Shah
Hi, team. Congratulations on a fantastic set of results.
I would just like first a little bit if y'all can expand on the R&D center that y'all mentioned, and what is the idea behind that going ahead?
Nareshkumar Ramjibhai Patel
Thank you, Rikin. The R&D center which we are doing is for upgrading and announcing our capability and capacity with our existing R&D center, because our existing R&D center is having a capacity which can cater all the requirement, but that we are expecting lot more inquiries and more traction towards the new molecule.
We don't want to be remain out of capacity when it came. That's why we decided to have a new expanded R&D center, and this R&D center will be equipped with facilitating all the vertical in a chemical sector which we are catering right now.
It is designed in a single complex with all multiple outlets in the chemical sector.
Rikin Shah
Got it, sir. Thank you so much for that.
Another question. Naturally, if I see our spec chem business is not relatively grown as quickly as our advance intermediates business, and thanks to our marquee CDMO project, the differential is far higher at this point.
Going forward, within even within advance intermediates per se, we have spoken about churning out lower-margin products in Q3. What is the base business looking like today, and do we have any growth plans for the same for the next two financial years?
Thanks.
Abhishek Patel
Basically, as we mentioned, we had some portfolio reshuffling for our pharma intermediate business ex of CDMO, and that has yielded a fruit in terms of margin expansion. I have already mentioned during my commentary that after nine months of FY26, it has grown sequentially in Q4 FY20—Q4 FY26, and expected to grow further in FY27 as well.
The volume-wise that business has grown despite of being flat in terms of revenue. Obviously, going forward, we are expecting good kind of revenue expectation from our ex CDMO CMO business also.
Now coming to your question related to spec chem business, we have to understand that the initially what the business we acquired through an acquisition of site, that business has grown in the range of 12% to 15% despite of some price reduction. Now this segment is expected to grow with additional revenue coming in from battery electrolyte additive space, and that the plant has already been constructed and the production has started.
This year we will have a very good exponential growth coming in from spec chem business as well.
Rikin Shah
Got it, sir. Within that, let's say, in battery chem, we had sent samples and now we've completed our first leg of capacity expansion.
In terms of contributing a little bit meaningfully to FY27, maybe if we cannot give a number on today, but do we have that sort of target or understanding inside that this segment will contribute meaningfully this year? I understand you have that sort of longer-term vision of scaling this as a big business, but in FY27, does this seem like a decent contribution?
Abhishek Patel
Definitely, in FY27, it will have a meaningful revenue contribution. It will start slowly with the Q1, and till Q4, it will keep on ramping on, and at the end of complete financial year FY27, we will definitely have a meaningful revenue contribution.
I will not put it any number to it as of now because there are many variables, but it will be a meaningful contribution.
Rikin Shah
Sure. Thanks, sir.
Are we taking any sort of contribution from the two new electrolytes we have added, or this is just the two products we have discussed before?
Abhishek Patel
As I mentioned, the capex is already going on for the third electrolyte additive product, and which is getting completed by Q2—Q1 FY27. Once that gets completed, it will also start contributing in the revenue.
The fourth product, we are in the phase of business development.
Rikin Shah
Got it. Within the CDMO piece, we have now, I think, a basket of five products other than the key project that is going on today, and we have been in the process of validation and approval with the innovators and originators.
The longer-term ₹1,000 crore guidance in CDMO for FY28 is intact. Within that, obviously, for FY27, do these four to five products also contribute something?
Abhishek Patel
Yes, definitely. As we mentioned, those are all validated products, and we are building it a good revenue expectation from this four products all as well, apart from the first product.
Rikin Shah
All right. Last question from my side—
Operator
Sir, Rikin Shah, sir, please, two questions per participant, sir.
Rikin Shah
Please
Operator
get back into the queue, sir. Thank you.
I'll join the queue.
Rikin Shah
Yeah. Yeah.
Operator
Ladies and gentlemen, in order to ensure that the management is able to address questions from all participants in the conference, please limit your questions to two, one or two per participants. Should you have a follow-up question, we would request you to rejoin the queue.
We have next question from Bharat Shah from Motilal Oswal Financial Services. Please go ahead, sir.
Bharat Shah
Hearty congratulations, Nareshbhai and the entire Aequitas team. Once again, very very robust delivery.
I had only one suggestion to make, and which is in general the feature of Indian corporate sector per se. You see, a lot of businesses which have been successful over a period of time, but remain underinvested in building the future by underinvesting into the innovation pipeline, underinvestment into research and development capability, in short, building the future.
Software services businesses is an example of that, where huge cash flows, but very limited investment into building the future technology, and therefore the struggle is evident as we have seen. Similarly, we have seen in consumer businesses in India, which have been very successful, but underinvested in the new consumer-facing technology and the way of delivering.
Even a lot of banks are underinvested in technology to build it in the contemporary manner. Therefore, Aequitas, which has displayed remarkable capability in a relatively smaller size of our operation, I don't think we should remain limited in ambition by our current size.
If we want to build the future, I think meaningful, intelligently kind of planned within our balance sheet capability, but sustained investment in building future is absolutely vital, especially in a chemical business like this, because otherwise the business will get commoditized at some stage. To kind of summarize, if you don't want the business to be commoditized, investing into the future to build it is an absolutely very vital one.
We have done very well by taking up intelligent bets, and here to consolidate. I think we shouldn't get deterred by our current size in order to build our future, which can be very exciting.
I thought I'll just put in that word, Nareshbhai. Once again, hearty congratulations, very delightful results, and entire team deserves the credit, and congratulations.
Abhishek Patel
Thank you, Bharat. It's a good advice, and it is coming from the veteran.
It's really meaning to us. If you remember, if you find my commentary, I said that we are going to be put up a new R&D center, which will be versatile.
It is not a conventional R&D center, but it is a versatile R&D center, which will be cater the across the sector of a semiconductor, electronics, electrical, battery, pharma, agro, and the cosmetics. It's a versatile R&D center with a different segment.
You are rightly say that we need to invest into the innovation, and this is what we do continuously. Initially, we started with a conventional chemistry to the flow chemistry, which is successfully imparted and now commercialized, then we enter first in India in the electrolyte, then in semicon.
We continuously making ourselves learning and then putting into the system and then executing it. We've taken serious note on that what you suggested, and in future, we will keep in mind when we do any new things.
Thank you very much, Bharat.
Bharat Shah
Absolutely pleasure, and once again hearty congratulations.
Abhishek Patel
Thank you, sir.
Operator
Thank you. Next question is from Garvit Goyal from Seren Alpha.
Please go ahead, sir.
Garvit Goyal
Hi, am I audible?
Operator
Yes, you are.
Garvit Goyal
Good evening, sir, and congrats for a good set of numbers. My first question is on the goodwill.
Can you please elaborate on this increase in the goodwill happened in FY26 over FY25, specifically if this pertains to the Indichem, which is a newly incorporated entity? I would like to understand what is the rationale for goodwill at this stage.
Further, can you also give some clarity on the basis for which the management is showing the confidence on the recoverability of this total goodwill of ₹104 crore? That's my first question, sir.
Bhavin Shah
When you talk about ₹104 crore, it has a two part. One goodwill which was created in the past, that was towards the acquisition of our BFC business.
For the year, there is an addition of around ₹48 crore in the goodwill. When we have made an investment of ₹190 crore in Indichem, the partner has bring in the capital that was at par value only.
For 25%, which is there for our partner, whatever we have paid ₹190 crore, out of that 25% is going towards the goodwill in our books of account. Now, since this is the investment we have made, and we are very much confident that this business in coming years is going to do excellently well, there is a valuation also attached to it basis the future projection.
This has been correctly account as per the accounting standard guided by ICAI.
Garvit Goyal
Regarding this partner with this JV, what is the background of that partner, what kind of expertise they are bringing in? Because this JV is not having any revenue so far, booking the goodwill means something which I'm not able to understand.
Maybe they are bringing some tech. Can you please elaborate on that part?
Abhishek Patel
First, about the background of our partner, he has been working in this space for more than 30 years, he is a veteran in this business, understand the Korean ecosystem well, apart from the international customer outside Korea like Taiwan and Japan. He has assembled a good team of people coming from the production and R&D and regulatory side.
This how we have joined hands with our partner. Your question related to goodwill, as Bhavinbhai has mentioned, for this JV, all the financial investment has been done by Aequitas, and we have given the 25% equity to the partner.
That's the reason we have to account 25% of those investment in the goodwill as per accounting standard. This is how it is going.
As we mentioned, we have a good confidence on our business with the projection going on, and we see that definitely the goodwill is recoverable in future.
Garvit Goyal
Got it. Sir, revenue contribution from Baba Fine Chemicals has remained limited, and now we are doing this JV with Indichem.
Just wanted to understand from you how do the product offerings of Indichem and Baba Fine Chemicals complement each other? Are there any clear synergies in the terms of products, in the terms of customers, or maybe in the terms of end applications, sir?
Abhishek Patel
No, we mentioned previously also, for our semiconductor business, we have two different stream of revenue. One is our Baba Fine Chemicals business, and then in Korea, it is a advanced stage product than what we offer in BFC.
Which is different from what BFC is manufacturing for HARIAS. These are more value-added product and a different stream of revenue.
Garvit Goyal
Okay. What kind of peak revenue are we anticipating maybe from this capex of ₹200 crore in Indichem?
Abhishek Patel
We are expecting around 1x kind of revenue from this plant.
Garvit Goyal
What kind of margin, sir?
Abhishek Patel
It is very premature to say as of now because it is in a construction phase, but generally you can expect a good margin from semiconductor business as an industry you study.
Garvit Goyal
Maybe in line with your specialty—
Operator
Garvit Goyal, sir, please return to the queue, sir.
Garvit Goyal
Just one last follow-up only. Maybe in line with the specialty chemical, sir?
Abhishek Patel
No, obviously not in line of this traditional specialty. It should be in line of the BFC business.
Garvit Goyal
Got it. Thank you, sir.
Thank you very much and all the best for the future. Thank you.
Abhishek Patel
Thanks.
Operator
Thank you. The next question is from the line of Sanil Jain from Ambit Capital.
Please go ahead.
Sanil Jain
Hi, sir. Am I audible?
Abhishek Patel
Yes. Yeah.
Sanil Jain
Congratulations on a good set of numbers. I just have couple of questions.
The first question from my side is, can you give us some developments on the new CDMO products under progress other than the Formion contract, and what can be the potential opportunity size of it?
Abhishek Patel
Okay. Obviously, we have a long pipeline of CDMO products, but we have announced validation of four more products after the first one.
When we say validation, it's a commercialized product already submitted to the customer, and now it's a process of getting regulatory approval from those. Once that gets completed, it will keep on going on large quantity.
In terms of revenue potential, we are expecting those products to be between ₹50 to ₹100 crore each at a peak level.
Sanil Jain
That's ₹50 to ₹100 crore each, right?
Abhishek Patel
Each, right.
Sanil Jain
Okay. The second question is that we have reported excellent EBITDA margins of 42%.
Can you tell us what was the EBITDA margin for specialty chemicals and advance intermediates separately?
Abhishek Patel
For our pharma business, for this quarter, EBITDA margin is around 44%, and for specialty, it is around 13%.
Bhavin Shah
29%.
Abhishek Patel
For pharma it is 44% and for specialty it is 29%.
Sanil Jain
29%, okay. Just one more, that are we planning to expand our Formion capacity, given the improved outlook by the innovators?
Abhishek Patel
As we earlier also said that we have got good visibility from this particular CDMO contract, and we have already built our capacity, which can suffice those production requirements.
Sanil Jain
Understood. Thank you.
That's it from my side.
Operator
Thank you. The next question is from the line of Nikunj Gupta from Enam Investment.
Please go ahead.
Nikunj Gupta
Yeah. Hello, am I audible?
Operator
Yes, sir.
Nikunj Gupta
Yeah. Hi, team.
Congratulations for the great set of numbers. My first question is, previously we had talked about semiconductor chemical shipments to Japanese and Korean customers, has it already been started?
Abhishek Patel
Yes.
Nikunj Gupta
Okay. My next question is, what is the revenue potential from the semiconductor chemicals and battery chemicals business over the next 3 to 5 years, and also if you can put some light on EBITDA margins as well, that would be very helpful.
Abhishek Patel
For electrolyte additive business is a function of capacity what we have built in, and as of now, the capacity for electrolyte additive is 2,000 metric tons for VC and FEC. Based on that, you can see the revenue potential coming in from that business.
Related to semiconductor business, that business has been going through some difficult phase in last financial year, but now it has recovered from Q4 onwards, and it will continue to ramp up in future also.
Nikunj Gupta
Okay. Yeah.
Thank you, team, and all the best for the future.
Operator
Thank you. The next question is from the line of Sai Kumar from Family Fund.
Please go ahead.
Sai Kumar
Yeah. Hi, sir.
Congratulate on a great set of numbers. My question is on that, sir, this year you have consolidated a yearly EBITDA margins around 34.5%, somewhere around 35.
For the FY27, what kind of range you are expecting?
Abhishek Patel
As I mentioned during my commentary also, we are expecting similar kind of margin in FY27 also. For us, margin is a function of product mix, and we expect similar kind of product mix in FY27.
That's the reason we see that it should be in a similar range only.
Sai Kumar
Okay. Got it, sir.
Regarding this Indichem JV, you said around end of FY26 you are going to commercialize the plant. When can we expect the supplies, and do we need to go any validation phase for that molecules, and when can we expect the commercial revenue from that Indichem JV?
Abhishek Patel
As soon as the plant gets constructed, we will have a commercial production going on from that plant. As Nareshbhai mentioned during his commentary that we have already started our R&D center in Indichem, and we have already started supplying the samples to the customer.
Parallelly, by the time the capex complete, we should have some customer onboarding happening, it can make our process faster in terms of commercial production ramp-up.
Sai Kumar
Okay. Got it, sir.
One last question. I see, in the China, for the BYD shifting more of their battery from lithium to sodium-ion.
What is the risk you see for that shift coming for sodium-ion batteries? Or else do you supply the molecules eligible for sodium-ion battery technology as well?
Nareshkumar Ramjibhai Patel
See, sodium-ion battery is not a new. It is started inventing 7, 8 years back, and now it is slowly slowly maturing, whereas lithium battery has still potential of next 10, 15 years.
It's not that 100% replacement of sodium-ion battery with lithium. Whatever we are targeting is even not a 1% of the demand.
For us, it's not an impact. Contrarily, whatever the new molecule which is coming into the electrolyte segment, there are some which is also going in this kind of area, but we can't disclose based on our contract.
It's a confidential for us, but yes, whatever the segments are working in electrolyte battery area, either it's a sodium or lithium or solid-state battery, we are there. We are trying to be supply our molecule in that segment, okay?
Sai Kumar
Got it, sir. One last question, sir—
Operator
Thank you, sir. Please limit your questions to two, sir, for fairness to all.
Sai Kumar
Thank you. Thank you.
Operator
Thank you. The next question is from the line of Jason Soans from IDBI Capital.
Please go ahead.
Jason Soans
Sir. Thank you so much for taking my question.
First question just wanted to know the capacity utilization for the Sachin plant, the Jhagadia plant, and the Ankleshwar facility.
Abhishek Patel
For this quarter under review, Q4, utilization at Sachin plant is 75%, Unit 2 Ankleshwar is 31%, and Unit 3 Jhagadia is 50%.
Jason Soans
Jhagadia is 50%, okay. Right.
Sir, just wanted to also understand, we said that the EBITDA margin for specialty chemicals in this quarter is 29%, right? Now, generally the margins are quite low, 15%, 20%, that is the kind of margins we clock.
Just wanted to know what is the reason for this jump.
Nareshkumar Ramjibhai Patel
Jason, we need to understand that chemical segment includes our traditional product as well as semiconductor and electronic business. For the quarter, we have seen a very good growth in the BFC business, which has a very high EBITDA margin and which is recovering from Q4 onwards.
Because of this, we have seen a better margin in chemical segment.
Abhishek Patel
Basically, that's a mix of both traditional spec chem margin as well as the BFC product margin.
Jason Soans
Battery chemicals also will be a part of this only, right, the specialty chemicals?
Abhishek Patel
Yes, it is part of this business only.
Jason Soans
It is a part of this business, okay. Just one question if I might just add on.
Sir, just, I understand 2,000 tons of the both products in the battery chemicals electrolyte additive segment. Just wanted to understand, sir, what utilization are we looking at?
Just you have those binded by long-term contracts, you would have some idea if you could give some color, whatever possible, of what revenue we can look at in FY27. Yeah.
Abhishek Patel
Yes. We have 2,000 metric ton capacity for both
Jason Soans
VC
Abhishek Patel
and FEC each. As we mentioned during our last commentary also that this plant is fully covered, backed by the customer contracts for all the capacities in next 3 years' time.
I will not put in any figure around the capacity utilization expected in this financial year, but as I mentioned during our first Q&A that production has already started, and it will keep on adding quarter-on-quarter from first quarter to fourth quarter, and it will definitely have a meaningful contribution from electrolyte additive space.
Jason Soans
Sure. Thanks, sir.
I'll join back the queue. Thank you so much.
Operator
Thank you. The next question is from the line of Raj Agrawal from Niveshaay.com.
Please go ahead.
Raj Agrawal
Hello.
Operator
Yes, sir, you are audible.
Raj Agrawal
Yes, sir. Thank you so much for the opportunity, and congratulations for a great set of numbers.
Sir, I had a question on CDMO business. We have a lot of these new businesses like battery chemicals and semiconductor chemicals that are scaling up.
We have guided for 25% kind of a growth for the next year. Are we anticipating any kind of slow down in CDMO, or basically if CDMO performs well, then we can surprise on the upside?
No, we are guiding 25% growth with mix of all the vertical and over the total top lines what we have achieved in 2000 FY26. Got it, sir.
Sir, on the margin side, this CDMO business as a whole has a relatively higher margin, right? This battery chemical business and our specialty chemical business on the other hand does not have that kind of margin profile.
Will it be difficult to maintain the current margin profile in FY27, or we will be able to do it with the current mix?
Abhishek Patel
As I mentioned during my commentary also, we are expecting similar kind of margin in FY27 because, as I said, the margin is a function of product mix, and we are expecting similar kind of product mix in FY27 as well. As I mentioned, there will be some meaningful contribution coming from electrolyte additive space, but there is a additional delta coming from CDMO business also.
That's the reason we are expecting similar kind of margin. Sir,
Raj Agrawal
just one last thing on this. If you can just explain what do you mean by the mix will remain the same, because the mix will change, right, because you have new business that is entering this mix?
Abhishek Patel
As I said, there is some portion of additional revenue coming from the spec chem business because of battery electrolyte additive segment, and there is a CDMO additional revenue also coming. Percentage-wise, it looks similar.
Raj Agrawal
Got it, sir. Thank you so much, sir.
Those were my questions.
Operator
Thank you. The next question is from Mehul Panchwani from 40Cents.
Please go ahead.
Mehul Panchwani
Hello, sir. Congratulations on a great set of numbers.
My first question is, what proportion of our growth in FY27-28 is backed by confirmed orders and long-term contracts across CDMO and the battery chemical segment?
Abhishek Patel
For CDMO business, as I mentioned for first customer, we have long-term supply contract already in place for 10 years, so that's backed by good visibility from the customer. On the electrolyte additive space also, as I just mentioned, we have already got customer contract in place and already signed.
Mehul Panchwani
Right. Sir, because I'm new in tracking our company.
You mentioned in one of the responses that we have a partner who is having 30 years of experience. Is it a firm or it's an individual, or can you just elaborate on the contract which we have signed with that entity?
Abhishek Patel
The contract which we have entered is a proprietary firm, and the experience of that partner, which I just mentioned during our Indichem business partner profile.
Mehul Panchwani
Thank you so much, and thanks. All the best.
Operator
Thank you, sir. The next question is from the line of Krishan Parwani from SBI Mutual Fund.
Please go ahead.
Krishan Parwani
Yes. Hi, sir.
Many congratulations on once again a great set of numbers. Just two questions.
First, on the CDMO pipeline, I believe, we had certain products in the validation phases in the last quarter, and we expected them to commercialize in the first half of FY27. Wanted to know has there been any update on this new product?
Are they commercialized yet? That's question number one.
Abhishek Patel
These are already commercialized product because plant validation batches are already supplied. Now, it's not in our hand or customer's hand because it's a regulatory approval.
We have already got some projection from the customer, so that's the reason I'm saying in FY27, we will definitely have a revenue coming from other four CDMO as well.
Krishan Parwani
Four CDMO, okay.
Abhishek Patel
Right, apart from the first one.
Krishan Parwani
Okay. The ramp-up of those will be majorly seen in FY28, correct?
Abhishek Patel
Yes.
Krishan Parwani
Okay. That's great, sir.
Secondly, on the margins, I believe, Abhishek, you mentioned margins at a similar level as 4Q or similar level to FY26?
Abhishek Patel
Similar level as FY26. Q4 is too ambitious.
Krishan Parwani
Ambitious is good, but okay, no problem. 36% is also great.
Just lastly, if I may squeeze one more. This Baba Fine Chem, I think Nareshbhai in his opening remarks mentioned that there is a strong traction that you expect over the next 2 to 3 years for the Baba Fine Chem.
Are the things really picking up pace right now, or what stage are we? Just some insights on that would be helpful.
Abhishek Patel
Just we mentioned that in Q4, the spec chem EBITDA was 29%, driven by the very good recovery in business of Baba Fine Chem in Q4. That's a sign of already recovered business for BFC, and we have similar kind of visibility for FY27 as well.
Krishan Parwani
Okay. I believe you don't need to do a large capex for the BFC because I think you didn't mention in the plan.
Is that correct?
Abhishek Patel
Yes, that's correct.
Krishan Parwani
Sir. Thank you so much for patiently answering my question, and wish you all the best.
Thank you so much, sir.
Abhishek Patel
Thanks.
Operator
Thank you. The next question is from the line of Hemant as Individual.
Please go ahead.
Sir, thank you for providing me the opportunity, and congratulations on a very good set of numbers. Sir, what I understand is that since you have guided for 25% kind of revenue growth in FY27, I think the main contributor will be the electrolyte additive division, right?
If I take a little longer view, maybe from FY28 and all, what can be the growth drivers for the company, sir? No,
Abhishek Patel
it's not only electrolyte additive which will be driving growth for FY27. Both our pharma intermediate business is also growing very fast, and that is the biggest engine for us for the growth.
Then slowly slowly, this additive business is also taking charge for growth. Then we have a semiconductor business picking up.
First started with BFC, and then maybe next 2 to 3 years' time, it should be from Indichem as well. There are three different growth engine which is driving our growth for next 3 years.
Can we expect a similar kind of run rate, sir? I think we had earlier mentioned the 25% kind of revenue growth till FY28, I guess in one of the previous concalls.
Can we expect the same?
Abhishek Patel
Yes, we have always guided that we are growing 25% growth, that's our history for more than a decade, and this is how we guide the market also bringing forward also.
Any other, sir, major capex lined up, and what is the contribution from CDMO side, because I think we have a guidance of ₹1,000 crore of revenue from CDMO by FY28?
Abhishek Patel
Yes, that is the guidance, correct. On a capex side, I have already mentioned that for next year, our capex will be the sum of the spillover of FY26 capex, which is around ₹50 crore, and around ₹40 crore will be from maintenance capex.
Then there will be capex around the R&D center and land, but the figures are yet to get finalized. We will update at a relevant time.
Sir, no major growth capex— Sir,
Operator
Mr. Hemant, please get back into the queue, sir.
Thank you. We have follow-up question from Jayesh Shinde from IDBI Capital.
Please go ahead.
Jason Soans
Sir, thank you for taking my question again, right? I just wanted to ask you on the Indichem investment has been done.
Earlier in the last concall, you had guided for that the facility will be on stream by the start of CY27. Is that plan on, or has it been delayed or something like that?
Abhishek Patel
No, plan is on. In fact, it will be even earlier than what it was guided.
As I said that it should get completed in second half of calendar year FY20 calendar year '26.
Jason Soans
Okay. Sure.
Sir, what the capex you just mentioned, some spillover capex of this year, basically probably around ₹100 crore odd number for '27 capex should be fine, and after that for the R&D center, I know you would need to form up those numbers. So, ₹100 crore odd for '27 would be okay?
That would be a good figure?
Abhishek Patel
That is already planned capex,
Jason Soans
and then
Abhishek Patel
as I mentioned, the R&D and any other capex, we will update as and when it gets finalized.
Jason Soans
Okay. Sir, just lastly wanted to know, this, of course, we know the Formion contract is doing very well, and, sir, the numbers are there $5 billion kind of peak revenue potential by the next 3 to 4 years.
Just on the ground, how do you see this contract ramping up? Just wanted to get some color from your side how is it doing, label extensions, etc.
How do you see the contract ramping up for you?
Abhishek Patel
Those things are already available in the presentation of Bayer as well as Orion presentation, and they have also guided the market about the growth of those products. I think being their primary supplier, we should be the beneficiary of those business, and we have already guided the market that how the business is going on and further expected to ramp up in FY27 and going forward as well.
Jason Soans
Sure. Thanks.
Thank you so much, sir, for answering all these questions. Thank you so much.
Operator
Thank you. The next question is from Dhara Patwa from Vallum Capital.
Please go ahead.
Dhara Ganatra
Thank you for taking my question, sir. Just a follow-up on the previous participant.
You mentioned that there is a ₹50 crore spillover of capex that will be done in FY27. What is this ₹50 crore spillover, sir?
What is this capex towards?
Abhishek Patel
It is related to capex of electrolyte additive and the pilot plant.
Dhara Ganatra
Additive and pilot plant. Okay.
Thank you, sir.
Operator
Thank you. The next question is from the line of Mr.
Ankit Mittal, Individual Investor. Please go ahead.
Ankit Mittal
Yes, sir. Thank you for the opportunity, and congratulations for a great set.
Abhishek Patel
Thanks.
Operator
Mr. Ankit Mittal, we are unable to hear you.
Ankit Mittal
Yes, can you hear me now?
Operator
Yes, you are audible. Please go ahead.
Ankit Mittal
Yeah. I was asking for the first question, and that is with regards to the revenue growth guidance.
As you mentioned in the last questions reply, we already know about the Formion project and the growth guidance given by Bayer, which is for 50% growth in calendar year 2026. Given that we have that outlook from Bayer, and also we have this electrolyte business coming up in this financial year, wanted to know if we are being conservative in giving this 25% revenue growth guidance for this year, and if all the things remain in good condition with respect to this Formion project, we might have an opportunity to revise this guidance later in this year?
Abhishek Patel
We have always guided the market about 25% growth CAGR, and that has been our history, and we would be happy to revise our guidance if that business potential goes beyond those 25% at a relevant stage of this financial year.
Ankit Mittal
Secondly, on the seasonality of the business, which you mentioned in the introductory remarks, which is 40% in the first half and 60% in second half, but with this Formion contract this year, which is already being ramped up to a decent size, do you think that that seasonality will reduce this year, and the YoY decline which we usually see in the first quarter, that might be limited this year given that the kind of growth we are seeing in that Formion project?
Abhishek Patel
Yes, that is also expected in FY27 as well.
Ankit Mittal
Expected meaning in Q1, wanted to check if the usual seasonality will be there, because usually we see 20%, 30% revenue decline QoQ in Q1. Given that the significant ramp-up of Formion project—
Abhishek Patel
See, in fact, Formion contract was there in FY24 and as FY25 and FY26 as well, and the both year has shown the similar kind of revenue trajectory, Q4 Q1 to Q4. That's our history for more than decade.
Ankit Mittal
Okay. Any particular reasons why we see it, because we don't see similar seasonality when we look at the numbers from Orion or Bayer.
Any particular reasons why we see at Aequitas level?
Nareshkumar Ramjibhai Patel
Sir, my company's history is that we have always Q1 is lower than Q2, Q2 is lower than Q3, Q3 is lower. In last 15 years, it's like that.
We are not only dealing with Formion, we have more than 600 customers. Each customer has different requirement at different time, and we have more than 100 products.
It's my company's seasonality and working like that. I'm not representing Formion.
Ankit Mittal
Sure. Thank you.
Thank you, and all the best. Thank you.
Operator
Thank you. Ladies and gentlemen, due to time constraint, we will take this as the last question.
I now hand the conference over to management for closing comments. Over to you, sir.
Nareshkumar Ramjibhai Patel
Thank you, 360 ONE Capital team, for hosting our conference call. We appreciate everyone's questions and hope we have addressed most of your queries.
If we missed any of your questions, please reach out to our investor relations team, and we will get back to you. Once again, thank you very much, and good evening to all of you.
Operator
Thank you. On behalf of Aequitas Chemicals Limited, that concludes this conference.
Thank you for joining us, and you may now disconnect your lines. Thank you.
Already premium?